Inactive Instrument

News Tiziana Life Sciences PLC London S.E.

Equities

GB00B28XMY25

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Jan. 08	Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	CI
Jan. 05	Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 11	AQ
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease	Mar. 05	AQ
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	AQ
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	CI
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	Jan. 05	MT
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024	Jan. 05	AQ
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05	AQ
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05	CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 30	CI
Tiziana Life Sciences : Updated Interim Results for the Six Months Ended 30 June 2023 - Form 6-K	Dec. 29	PU
Tiziana Life Sciences : Interim Results for the Six Months Ended 30 June 2023 863.7 KB	Dec. 29	PU
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis	Dec. 19	AQ
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis	Dec. 19	CI
Transcript : Tiziana Life Sciences Ltd - Shareholder/Analyst Call	Dec. 14
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar	Dec. 04	AQ
Tiziana Life Sciences : Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK - Form 6-K	Dec. 01	PU
Tiziana Life Sciences Doses Four New Patients in Multiple-Sclerosis Program	Nov. 30	MT
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis	Nov. 30	CI
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis	Nov. 30	AQ
Tiziana Life Sciences : Notice of Annual General Meeting December 2023	Nov. 23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tiziana Life Sciences PLC London S.E.

Equities

GB00B28XMY25

Summary

Filters